HFSA 2024 - We are joined by Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) to discuss the findings from HuMAIN HFpEF, a phase 2A randomized, parallel-group, placebo-controlled study of HU6 in patients with obesity and heart failure with preserved ejection fraction (HFpEF).

Interview Questions:

1. What is the reasoning behind this study?
2. Could you tell us about the mechanism of action behind HU6?
3. What was the study design and patient population?
4. What are the key findings?
5. What are the implications for clinical practice?
6. What further study is needed, and what are the next steps?

Recorded remotely from Dallas, 2024.

Editor: Jordan Rance

Video Specialist: David Ben-Harosh